BIOCHEMISTRY OF DIABETES MELLITUS PATHOGENESIS: THE UNIFYING MECHANISM OF HYPERGLYCEMIC DAMAGE AND QUANTITATIVE ASSESSMENT OF METABOLIC PATHWAYS

An Analytical Review

Juraev Mukhammadnazar Bakhodir Ugli
Professor
F.X. Inoyatova
PhD
Z.I.Galieva
Tashkent State Medical University, Department of Medical and Biological Chemistry No. 1; mukhammadnazard@gmail.com

Abstract: Diabetes mellitus is a metabolic disease defined by chronic hyperglycemia resulting from defective insulin secretion, defective insulin action, or both; oxidative stress represents the common biochemical denominator of β-cell damage and of the long-term complications of hyperglycemia [30]. According to the unifying mechanism proposed on the basis of two decades of experimental work, hyperglycemia-driven overproduction of superoxide by the mitochondrial electron transport chain links the four previously separate pathogenetic pathways — the polyol pathway, advanced glycation end product formation and RAGE signaling, protein kinase C activation, and the hexosamine pathway — into a single cascade of cellular damage [3]. This review presents the pathway-by-pathway biochemistry with its quantitative, laboratory-measurable markers (e.g., MG-H1 rising ~5-fold within 6 weeks and fructosyl-lysine from 6-fold at 3 weeks to 13-fold at 12 weeks in diabetic nerve endoneurial proteins [7]; serum GPX 45.1 ± 8.8 vs. 51.5 ± 9.2 U/gHb and NO 7.6 ± 0.9 vs. 8.9 ± 1.6 μmol/L in patients, $P < 0.05$ [16]), translates the molecular axes into the tissue pathology of diabetic peripheral neuropathy, and identifies mechanism-matched therapeutic counter-agents (α-lipoic acid, benfotiamine, aminoguanidine) — including glucose-independent neuroprotection by chitosan [27]. The article is written from a clinical-chemistry department's perspective: every pathogenetic axis is expressed as a measurable biomarker panel, directly transferable to experimental and clinical assessment of disease-modifying correction.

Keywords: diabetes mellitus; pathogenesis; oxidative stress; mitochondrial superoxide; advanced glycation end products; polyol pathway.

Introduction

Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia arising from defects in insulin secretion, insulin action, or both. The chronic elevation of blood glucose is not merely a laboratory abnormality — it is the proximate cause of the microvascular and neuropathic complications that determine the burden of the disease: diabetic peripheral neuropathy develops in approximately 50% of diabetic patients [4], and the resulting sensory loss, neuropathic pain and foot-ulceration risk dominate the clinical and social costs of diabetes [20]. The central therapeutic fact that defines the field is that glycemic control remains the only universally proven disease-modifying intervention, while the pharmacopeia directed at complications is largely symptomatic. For the biochemist, this situation poses a precise question: which molecular processes, set in motion by hyperglycemia, actually produce the tissue damage, and can each of them be measured? The present review answers this question by (i) describing the initiating biochemical insult in the pancreatic β-cell, (ii) presenting the unifying mechanism of hyperglycemic damage — mitochondrial superoxide overproduction — that links the four classic metabolic pathways, (iii) converting each pathway into its quantitative markers, (iv) using diabetic peripheral neuropathy as the worked example of how these molecular mechanisms become a clinical complication, and (v) identifying mechanism-matched therapeutic agents for correction.

The B-Cell And The Initiating Oxidative Insult

Insulin secretion is metabolically coupled to glucose concentration: glucose enters the β-cell, is metabolized through glycolysis and mitochondrial oxidation, and the resulting rise in ATP (and in the ATP/ADP ratio) closes ATP-sensitive K^+ channels, depolarizing the membrane and triggering Ca^{2+}-dependent exocytosis of insulin granules. This coupling makes the β-cell exquisitely sensitive to its own metabolic and oxidative state. Chronic hyperglycemia and elevated lipids generate oxidative stress within the β-cell, which suppresses insulin gene expression and insulin synthesis and increases β-cell apoptosis; the endocrine pancreas possesses a low intrinsic capacity for detoxifying reactive oxygen species, which renders it particularly vulnerable [14]. Oxidative stress and diabetes are therefore bidirectional: hyperglycemia generates ROS, and ROS in turn impair both insulin secretion and insulin action, propagating the disease. This initiating oxidative insult is the biochemical root from which all four downstream pathways of hyperglycemic damage emerge.

For years the polyol, AGE, PKC and hexosamine pathways were regarded as independent hypotheses of hyperglycemic damage. The unifying mechanism proposed that they share a single upstream trigger: under hyperglycemia, the increased flux of glucose through glycolysis and the tricarboxylic acid cycle

overloads the mitochondrial electron transport chain, raising the mitochondrial membrane potential and driving excessive generation of superoxide. The key molecular step is inhibition of glyceraldehyde-3-phosphate dehydrogenase: superoxide activates poly polymerase, which depletes intracellular NAD^+ and thereby inactivates GAPDH. The glycolytic intermediates that accumulate above the GAPDH block — glucose, fructose-6-phosphate, triose phosphates, and methylglyoxal precursors — are then diverted into the four damaging pathways: increased polyol flux, increased hexosamine flux, increased de novo diacylglycerol synthesis with PKC activation, and increased formation of AGEs [3]. The decisive experimental proof of unity is that preventing the mitochondrial superoxide overproduction — by overexpressing manganese superoxide dismutase or by uncoupling the electron transport chain — simultaneously blocks all four pathways [3]. The same superoxide mechanism inactivates endothelial nitric oxide synthase and prostacyclin synthase and drives NF-κB-dependent expression of pro-inflammatory genes [24]. The NF-κB axis is particularly important for diabetic neuropathy: it is the molecular bridge from hyperglycemia to neuroinflammation in the peripheral nerve [6].

Pathway-By-Pathway Biochemistry With Quantitative Markers

Polyol (aldose reductase) pathway. Under normoglycemia, the low-affinity aldose reductase enzyme is minimally active; under hyperglycemia, glucose is reduced to sorbitol at the expense of NADPH, and sorbitol is oxidized to fructose by sorbitol dehydrogenase with reduction of NAD^+ to NADH. The pathway consumes NADPH — the cofactor required for regeneration of reduced glutathione — thereby directly coupling polyol flux to depletion of the antioxidant defense [8]. The pathway was validated as a therapeutic target biochemically: treatment with the aldose reductase inhibitor sorbinil prevented the diabetes-induced decline in peripheral nerve conduction velocity and attenuated polyol accumulation [5]. Hexosamine pathway. When the glycolytic block diverts fructose-6-phosphate into the hexosamine pathway, glutamine: fructose-6-phosphate amidotransferase converts it to glucosamine-6-phosphate and ultimately to UDP-N-acetylglucosamine, the donor for O-GlcNAc modification of proteins. O-GlcNAcylation of transcription factors such as Sp1 up-regulates pro-fibrotic and pro-thrombotic genes including TGF-β and plasminogen activator inhibitor-1 [3]. The pathway is measurable biochemically by flux through GFAT and by tissue UDP-N-acetylglucosamine content, though it is less commonly quantified than the AGE and oxidative markers in diabetic nerve studies. PKC pathway. The triose phosphates accumulating above the GAPDH block are converted to DAG de novo, activating protein kinase C — predominantly the β and δ isoforms. PKC activation produces the vascular dysfunctions of diabetes: reduced endoneurial

blood flow, endothelial permeability, and activation of NF-κB-dependent inflammatory signaling [3]. In peripheral nerve, PKC-mediated microvascular impairment is mechanistically linked to the earliest conduction slowing, which is why the metabolic phase of neuropathy is vascularly reversible in its early stage [1]. AGE formation and RAGE signaling. Non-enzymatic glycation attacks free amino groups of proteins, yielding early products (fructosyl-lysine) and, after oxidative rearrangement, advanced glycation end products (including MG-H1, the most abundant AGE residue, and the crosslink pentosidine). Quantitatively, in the endoneurial matrix proteins of diabetic rats the MG-H1 content rises ~5-fold within 6 weeks, and fructosyl-lysine rises from a 6-fold increase at 3 weeks to a 13-fold increase at 12 weeks [7]; in human sural nerve, pentosidine is significantly elevated in cytoskeletal and myelin proteins [2]. Glycation is not merely a marker — it is functionally destructive for nerve repair: neurite outgrowth on methylglyoxal-glycated laminin falls from 160 ± 28 to 90 ± 18 cross-points, and from 32 ± 3 to 17.4 ± 3 at 100 µm from the cell body ($P \leq 0.05$) [7]. AGEs also act through the RAGE receptor to drive NF-κB and pro-inflammatory gene expression [6]. The pivotal biochemical fact for the correction strategy is that AGE inhibition is glucose-independent: 16 weeks of aminoguanidine reduced accumulation of fluorescent AGEs in the nerve and improved motor nerve conduction velocity while body weight, blood glucose and HbA1c remained unchanged [28]. This is the direct precedent for the hypothesis that structural and functional nerve protection can be achieved without glycemic normalization. Glucose autoxidation and the shared oxidative root. Finally, hyperglycemia directly promotes ROS generation through glucose autoxidation and the mitochondrial mechanism described above; oxidative stress is thus both the initiator and the amplifier of the other pathways — a "radical approach" in which all secondary pathways converge on oxygen radicals [10]. ROS attack lipids (lipid peroxidation), proteins, and nucleic acids, exhausting glutathione and the antioxidant enzymes [14]. Oxidative stress is the axis with the richest quantitative evidence, and it is the axis around which the planned experimental panel is organized. The following markers are consistently reported and directly transferable to laboratory practice:

Marker	Biological sample	Reported diabetic shift
MDA + 4-hydroxyalkenals	Sciatic nerve homogenate	Increased [9]
GSH	Sciatic nerve homogenate	Decreased [17]

SOD, catalase	Nerve homogenate (0.1 mol/L sodium phosphate buffer pH 6.5; 20,000 g, 20 min)	Activity decreased [17]
SOD, GSH-Px, MDA	Serum	SOD and GSH-Px decreased, MDA increased ($p < 0.01$) [31]
GPX, NO	Serum (patients)	GPX 45.1 ± 8.8 vs. 51.5 ± 9.2 U/gHb; NO 7.6 ± 0.9 vs. 8.9 ± 1.6 µmol/L ($P < 0.05$) [16]
Nrf2/HO-1 axis	Nerve tissue	Activation is protective; decreased Nrf2 amplifies inflammation and degeneration [14]

The protective arm of this axis — the Nrf2/HO-1 system — is the mechanism by which antioxidants maintain cellular redox homeostasis [14]; its activation in the peripheral nerve and in Schwann cells reduces oxidative stress and apoptosis, and its decline is considered a central link in the amplification of inflammation and axonal degeneration [27]. The value of the unifying mechanism is that it predicts where, at tissue level, the damage appears. In the diabetic peripheral nerve, the four biochemical axes of this thesis are the direct tissue expression of the four pathways of hyperglycemic damage: Oxidative stress in nerve and serum, exactly as quantified in Section 5 — the sciatic nerve shows increased MDA and decreased GSH [9], and serum SOD/GSH-Px fall while MDA rises ($p < 0.01$) [31]. Glycation/AGE accumulation in the endoneurial matrix (Section 4.4), which not only marks but actively suppresses regeneration [7]. Neuroinflammation — NF-κB, TNF-α, IL-1β, IL-6 elevated in sciatic nerve and dorsal root ganglia, driven by the AGE–RAGE superoxide axis; delivery of PARP-1 siRNA in chitosan nanoparticles down-regulates these pro-inflammatory mediators together with the apoptotic proteins CAS3, CAS9, BAK and BAX, significantly improving the sciatic functional index and motor nerve conduction velocity ($p < 0.001$) [19]. Schwann-cell endoplasmic reticulum stress and apoptosis — high glucose (30 mM, RSC96 Schwann cell line) elevates ER-stress proteins and triggers apoptosis, detected by TUNEL (DAPI counterstain, ×400) and Annexin V/PI flow cytometry; neurotrophic coacervates of NGF and bFGF suppress this apoptosis and restore regeneration and myelin integrity [18]. The structural correlate of Schwann-cell injury is the

axo-glial dysjunction — the characteristic lesion that accounts for poorly reversible slowing of nerve conduction in experimental diabetes [22]. Crucially for study design, the Neurodiab consensus on phenotyping rodent diabetic neuropathy describes the disease as a dynamic process with two phases: it begins as an acute metabolic phase — conduction slowing and hyperalgesia usually reversible — and progresses to a chronic structural phase that is "less amenable to metabolic interventions" [1]. The classic structural data agree: early paranodal axonal swellings and nodal bulgings were completely normalized by vigorous insulin therapy, whereas in the chronic phase the loss of axoglial junctions left conduction irreversibly impaired [22]; and early insulin treatment prevented the decrease in conduction velocity and fibre calibre [15]. This two-phase principle is the biochemical justification of the prevention design: intervention at diabetes confirmation, before the molecular damage matures into the structural phase.

Mechanism-Matched Therapeutic Counter-Agents

Because each pathway has its quantitative marker, each pathway also has its mechanism-matched counter-agent — the basis of the "correction" half of the thesis title: α-Lipoic acid (oxidative-stress axis). The evidence is dose-dependent: intravenous 600 mg improved major neuropathic symptoms within days, while 100 mg/day was indistinguishable from placebo [33]; orally, 600/1200/1800 mg/day for 5 weeks reduced the Total Symptom Score by 4.9 (51%), 4.5 (48%) and 4.7 (52%) points versus 2.9 (32%) with placebo [32]; the 4-year NATHAN 1 trial (460 patients, 600 mg/day) assessed the long-term disease course [34]. Benfotiamine (glycation axis). The lipid-soluble thiamine prodrug diverts glycolytic flux away from AGE formation. Short-term trials are positive — BEDIP (400 mg/day, 3 weeks) improved painful symptoms [13]; BENDIP (randomized, double-blind, placebo-controlled) supported a causal influence on impaired glucose metabolism [25]; a 12-week benfotiamine + B6/B12 combination significantly improved peroneal nerve conduction velocity ($p = 0.006$) [26]— but the 24-month randomized controlled trial in type 1 diabetes found nerve conduction parameters deteriorating at the same rate in both groups [11], leaving the long-term disease-modifying claim contested. Aminoguanidine. The glucose-independence precedent: improved motor nerve conduction velocity with unchanged blood glucose and HbA1c [28]. Chitosan (glucose-independent neuroprotection). Oral chitosan (medium molecular weight, 150 mg/kg/day, 12 weeks, starting 72 h after diabetes induction) preserved CMAP amplitude (6.756 ± 0.760 vs. 5.756 ± 0.706 mV in untreated diabetics, $p = 0.0409$) and attenuated the latency prolongation (1.553 ± 0.125 vs. 1.738 ± 0.146 ms, $p = 0.0418$) with no significant change in blood glucose (mean diff −22.25 mg/dL, $p = 0.3366$) — a "disease-modifying" profile

independent of glycemic control, attributed by the authors to antioxidant, anti-inflammatory and hypolipidemic actions on the Nrf2/HO-1 and NF-κB axes [27].

Conclusion

The biochemistry of diabetes mellitus pathogenesis can be summarized as one initiating trigger and four measurable pathways: hyperglycemia-driven mitochondrial superoxide overproduction [3] sets in motion the polyol, hexosamine, PKC and AGE pathways, each of which is quantitatively assessable — sorbitol flux (validated by sorbinil [5]), MG-H1 and fructosyl-lysine accumulation in nerve endoneurial proteins [7], NF-κB-driven cytokines [6], and the oxidative-stress markers MDA/GSH/SOD/catalase in nerve homogenate and serum [17]. At tissue level, these pathways converge in the four axes of diabetic neuropathy — oxidative stress, glycation, neuroinflammation, and Schwann-cell apoptosis [18]— which evolve from a reversible metabolic phase into a chronic structural phase [1], thereby defining the timing principle for intervention. The same pathways are addressable by mechanism-matched agents — α-lipoic acid on the oxidative axis [32], benfotiamine on the glycation axis [13], aminoguanidine as the glucose-independent AGE precedent [28]— and by glucose-independent neuroprotection with chitosan [27].

REFERENCES

1. Biessels, G. J., Bril, V., Calcutt, N. A., Cameron, N. E., Cotter, M. A., Dobrowsky, R. T., Feldman, E. L., Fernyhough, P., Jakobsen, J., Malik, R. A., Mizisin, A. P., Oates, P. J., Obrosova, I. G., Pop-Busui, R., Russell, J. W., Sima, A. A., Stevens, M. J., Schmidt, R., Tesfaye, S., … Zochodne, D. W. (2014). Phenotyping animal models of diabetic neuropathy: a consensus statement of the diabetic neuropathy study group of theEASD(Neurodiab). Journal of the Peripheral Nervous System, 19(2), 77–87. https://doi.org/10.1111/jns5.12072

2. Boulton, A. J. M., Malik, R. A., Arezzo, J. C., & Sosenko, J. M. (2004). Diabetic Somatic Neuropathies. Diabetes Care, 27(6), 1458–1486. https://doi.org/10.2337/diacare.27.6.1458

3. Brownlee, M. (2005). The Pathobiology of Diabetic Complications. Diabetes, 54(6), 1615–1625. https://doi.org/10.2337/diabetes.54.6.1615

4. Callaghan, B. C., Cheng, H. T., Stables, C. L., Smith, A. L., & Feldman, E. L. (2012). Diabetic neuropathy: clinical manifestations and current treatments. The Lancet Neurology, 11(6), 521–534. https://doi.org/10.1016/s1474-4422(12)70065-0

5. Cameron, N. E., Leonard, M., Ross, I. S., & Whiting, P. H. (1986). The effects of Sorbinil on peripheral nerve conduction velocity, polyol

concentrations and morphology in the streptozotocin-diabetic rat. Diabetologia, 29(3), 168–174. https://doi.org/10.1007/bf02427088
6. Chong, Z. Z., Menkes, D. L., & Souayah, N. (2024). Targeting neuroinflammation in distal symmetrical polyneuropathy in diabetes. Drug Discovery Today, 29(8), 104087. https://doi.org/10.1016/j.drudis.2024.104087
7. Duran-Jimenez, B., Dobler, D., Moffatt, S., Rabbani, N., Streuli, C., Thornalley, P. J., Tomlinson, D. R., & Gardiner, N. J. (2009). Advanced Glycation End Products in Extracellular Matrix Proteins Contribute to the Failure of Sensory Nerve Regeneration in Diabetes. Diabetes, 58(12), 2893–2903. https://doi.org/10.2337/db09-0320
8. Edwards, J. L., Vincent, A. M., Cheng, H. T., & Feldman, E. L. (2008). Diabetic neuropathy: Mechanisms to management. Pharmacology & Therapeutics, 120(1), 1–34. https://doi.org/10.1016/j.pharmthera.2008.05.005
9. Ekinci, B., Süleyman, B., Mammadov, R., Gezer, A., Mendĭl, A. S., Akbaş, N., Bulut, S., Dal, C., & Süleyman, H. (2023). The effect of carvacrol upon experımentally ınduced dıabetıc neuropathy and neuropathıc paın ın rats. Acta Poloniae Pharmaceutica - Drug Research, 79(5), 707–715. https://doi.org/10.32383/appdr/155354
10. Feldman, E. L. (2003). Oxidative stress and diabetic neuropathy: a new understanding of an old problem. Journal of Clinical Investigation, 111(4), 431–433. https://doi.org/10.1172/jci17862
11. Fraser, D. A., Diep, L. M., Hovden, I. A. H., Nilsen, K. B., Sveen, K. A., Seljeflot, I., & Hanssen, K. F. (2012). Response to Comment on: Fraser et al. The Effects of Long-Term Oral Benfotiamine Supplementation on Peripheral Nerve Function and Inflammatory Markers in Patients With Type 1 Diabetes: A 24-Month, Double-Blind, Randomized, Placebo-Controlled Trial. Diabetes Care 2012;35:1095–1097. Diabetes Care, 35(11). https://doi.org/10.2337/dc12-1124
12. Giacco, F., & Brownlee, M. (2010). Oxidative Stress and Diabetic Complications. Circulation Research, 107(9), 1058–1070. https://doi.org/10.1161/circresaha.110.223545
13. Haupt, E., Ledermann, H., & Köpcke, W. (2005). Benfotiamine in the treatment of diabetic polyneuropathy a three-week randomized, controlled pilot study (BEDIP Study). International Journal of Clinical Pharmacology and Therapeutics, 43(2), 71–77. https://doi.org/10.5414/cpp43071
14. He, L., He, T., Farrar, S., Ji, L., Liu, T., & Ma, X. (2017). Antioxidants Maintain Cellular Redox Homeostasis by Elimination of Reactive Oxygen Species. Cellular Physiology and Biochemistry, 44(2), 532–553. https://doi.org/10.1159/000485089
15. Jakobsen, J. (1979). Early and preventable changes of peripheral nerve

structure and function in insulin-deficient diabetic rats. Journal of Neurology Neurosurgery & Psychiatry, 42(6), 509–518. https://doi.org/10.1136/jnnp.42.6.509
16. Kasznicki, J., Kosmalski, M., Śliwińska, A., Mrowicka, M., Stańczyk, M., Majsterek, I., & Drzewoski, J. (2012). Evaluation of oxidative stress markers in pathogenesis of diabetic neuropathy. Molecular Biology Reports, 39(9), 8669–8678. https://doi.org/10.1007/s11033-012-1722-9
17. Kellogg, A. P., & Pop-Busui, R. (2005). Peripheral Nerve Dysfunction in Experimental Diabetes Is Mediated by Cyclooxygenase-2 and Oxidative Stress. Deep Blue (University of Michigan), 7, 1521–1529. https://doi.org/10.1089/ars.2005.7.1521
18. Li, R., Ma, J., Wu, Y., Nangle, M. R., Zou, S., Li, Y., Yin, J., Zhao, Y., Xu, H., Zhang, H., Li, X., Ye, Q., Wang, J., & Xiao, J. (2017). Dual Delivery of NGF and bFGF Coacervater Ameliorates Diabetic Peripheral Neuropathy via Inhibiting Schwann Cells Apoptosis. International Journal of Biological Sciences, 13(5), 640–651. https://doi.org/10.7150/ijbs.18636
19. Redhwan, M. A. M., M.G, H., Samaddar, S., Bafail, D., Hard, S. A. A. A., Guha, S., & Dhavale, A. (2024). siRNA targeting PARP-1 alleviates diabetic peripheral neuropathy in a streptozotocin-induced rat model. Journal of Drug Targeting, 33(3), 424–435. https://doi.org/10.1080/1061186x.2024.2431316
20. Rosenberger, D. C., Blechschmidt, V., Timmerman, H., Wolff, A., & Treede, R. (2020). Challenges of neuropathic pain: focus on diabetic neuropathy. Journal of Neural Transmission, 127(4), 589–624. https://doi.org/10.1007/s00702-020-02145-7
21. Schmidt, A. M., & Stern, D. (2000). A radical approach to the pathogenesis of diabetic complications. Trends in Pharmacological Sciences, 21(10), 367–369. https://doi.org/10.1016/s0165-6147(00)01537-6
22. Sima, A. A. F., & Brismar, T. (1985). Reversible diabetic nerve dysfunction: Structural correlates to electrophysiological abnormalities. Annals of Neurology, 18(1), 21–29. https://doi.org/10.1002/ana.410180105
23. Sima, A. A. F., Lattimer, S. A., Yagihashi, S., & Greene, D. A. (1986). Axo-glial dysjunction. A novel structural lesion that accounts for poorly reversible slowing of nerve conduction in the spontaneously diabetic bio-breeding rat. Journal of Clinical Investigation, 77(2), 474–484. https://doi.org/10.1172/jci112326
24. Singh, A., Kukreti, R., Saso, L., & Kukreti, S. (2022). Mechanistic Insight into Oxidative Stress-Triggered Signaling Pathways and Type 2 Diabetes. Molecules, 27(3), 950. https://doi.org/10.3390/molecules27030950
25. Stracke, H., Gaus, W., Achenbach, U., Federlin, K., & Bretzel, R. G. (2008). Benfotiamine in Diabetic Polyneuropathy (BENDIP): Results of a Randomised,

Double Blind, Placebo-controlled Clinical Study. Experimental and Clinical Endocrinology & Diabetes, 116(10), 600–605. https://doi.org/10.1055/s-2008-1065351
26. Stracke, H., Lindemann, A., & Federlin, K. (2009). A Benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy. Experimental and Clinical Endocrinology & Diabetes, 104(4), 311–316. https://doi.org/10.1055/s-0029-1211460
27. Țucă, A.-M., Albu, C. V., Preda, A. N., Dan, A. O., Târtea, E.-A., Greșiță, A., Pîrșcoveanu, D., Sfredel, V., Mitran, S. I., & Târtea, G. (2025). Chitosan Protects Peripheral Nerves Against Damage Induced by Diabetes Mellitus. Life, 15(12), 1860. https://doi.org/10.3390/life15121860
28. Yagihashi, S., Kamijo, M., Baba, M., Yagihashi, N., & Nagai, K. (1992). Effect of Aminoguanidine on Functional and Structural Abnormalities in Peripheral Nerve of STZ-Induced Diabetic Rats. Diabetes, 41(1), 47–52. https://doi.org/10.2337/diab.41.1.47